Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.39 |
| ▸ | SETD2 | Q9BYW2 | 1/20 | 0.37 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.36 |
| ▸ | FASN | P49327 | 6/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.34 |
| ▸ | CCR2 | P41597 | 1/20 | 0.34 |
| ▸ | ADAM10 | O14672 | 1/20 | 0.34 |
| ▸ | ACKR3 | P25106 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13640928 | 1.00 | HRH3 (0.39) | HRH3SETD2CHRNA7FASNKCNH2 | |
| SCHEMBL13640831 | 0.94 | CHRNA7 (0.38) | SETD2CHRNA7KCNH2ACKR3 | |
| SCHEMBL13640900 | 0.93 | CHRNA7 (0.38) | HRH3SETD2CHRNA7KCNH2ACKR3 | |
| SCHEMBL13640837 | 0.88 | CHRNA7 (0.39) | SETD2CHRNA7KCNH2CCR2ACKR3 | |
| SCHEMBL13640995 | 0.85 | CHRNA7 (0.41) | HRH3SETD2CHRNA7KCNH2ACKR3 | |
| SCHEMBL13640795 | 0.85 | CHRNA7 (0.39) | HRH3SETD2CHRNA7ACKR3 | |
| SCHEMBL13640938 | 0.84 | CHRNA7 (0.37) | HRH3SETD2CHRNA7KCNH2ACKR3 | |
| SCHEMBL13640848 | 0.84 | CHRNA7 (0.40) | SETD2CHRNA7 | |
| SCHEMBL13640994 | 0.83 | CHRNA7 (0.38) | SETD2CHRNA7ACKR3 | |
| SCHEMBL13640876 | 0.83 | CHRNA7 (0.39) | SETD2CHRNA7KCNH2ACKR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8497295-B2 | Spiroindoline modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-07-30 | — | — | US | disclosed |
| US-20120283243-A1 | Spiroindoline Modulators of Muscarinic Receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283243-A1 | Spiroindoline Modulators of Muscarinic Receptors | CHRM3, CHRM2, CHRM5 | HRH3 261/4885SETD2 3573/4885CHRNA7 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.